New Conviva Data Shows Streaming Platforms Holding Onto 2020 Pandemic Gains; International Markets Surging
11.8.2021 16:00:00 EEST | Business Wire | Press release
The streaming explosion, which hit its apex during the Covid-induced lockdowns in Q2 2020, is here to stay according to new data from Conviva, the intelligence cloud for streaming media. Conviva’s Q2 2021 State of Streaming report revealed streaming viewing time worldwide grew 13% in Q2 2021, as compared to Q2 2020. Despite a 7% decline in streaming viewing in April, North America still saw a 2% increase in streaming viewing in Q2 2021, compared to the same time last year. Other regions saw even bigger spikes in time spent streaming with Africa growing 79% and South America growing 192% year over year driven by the launch of new services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005256/en/
Q2 2021 State of Streaming from Conviva (Graphic: Business Wire)
In tandem with increased viewership, the quality of streaming ads also improved significantly in Q2 2021. Only 16% of ads represented missed opportunities as they went unfilled or failed to play as expected, down from 37% the previous quarter. While total ad attempts dropped 8% from Q1 to Q2 2021, more attempts were successful, resulting in a 4% increase overall in ad impressions. What’s more, in Q2 2021, viewers had a better experience with ads as they spent 31% less time waiting for ads to play and ad duration decreased 3% to 27 seconds.
“As the global streaming industry grows and competition becomes even more intense, consumer expectations for a superior streaming experience – premium content, consistent performance and high-quality ad creative – will only continue to rise,” said Keith Zubchevich, CEO, Conviva. “The publishers and advertisers that can meet or exceed these expectations will be rewarded with continued growth; however, failing to address any aspect of the viewing experience could spell disaster.”
Device Fragmentation; Roku Still Dominates
Big screens, including connected TV devices, smart TVs and gaming consoles, remained the dominant way to stream in Q2 2021, commanding 73% of global viewing time, down just 1% from Q2 2020 even as consumers spent less time home bound. Mobile phones captured that 1% share, growing from 10% in Q2 2020 to 11% in Q2 2021. While smart TVs continued their meteoric rise, up 46%, and connected TV devices saw moderate growth, up 5%, gaming consoles were the lone big screen streaming device to tally a significant decrease, down 14%. Among connected TV devices, Roku maintained its dominance with 31% global share of big screen viewing time, but dropped slightly in share as smart TV-only devices including Samsung TV, LG TV, Android TV, and Vizio TV each increased 1-2%.
Top Streaming Shows Being Discussed on Social
Streaming services are beginning to realize the immense value of social platforms as they promote their content and engage with consumers. Grey’s Anatomy, which promotes its streaming availability on Hulu, had the most cross-platform engagements on social media in Q2 2021, closely followed by Netflix’s Spanish-language drama Elite. Among new originals, Loki claimed the top social engagement spot for Disney+ at number four on Conviva’s list of the top streaming shows by social media engagement. Netflix was the streaming service most successfully driving engagements for its shows on social media with six shows noted on the list, followed by The CW with four of the top 25 shows.
The Fortune 500 and Social Videos
In addition to advertising on linear and streaming, the largest companies in the world continue to leverage video on social platforms as a way to engage with their customers. According to a Conviva analysis of the Fortune 500, McDonald’s, Netflix, Nike, Apple and Facebook all claimed top social spots in Q2 2021. Netflix tallied the most social media videos, most video views and highest total cross-platform engagements, while Apple had the highest average engagements per video and highest average engagements per post for the quarter. McDonald’s collaboration with the K-pop group BTS drove millions of engagements in Q2 2021, securing it the top spot for average cross-platform engagement rate for any brand with more than fifteen thousand followers.
To download the full report, visit: www.conviva.com/state-of-streaming
Methodology
Data for Conviva’s State of Streaming report was primarily collected from Conviva’s proprietary sensor technology currently embedded in 3.3 billion streaming video applications, measuring in excess of 500 million unique viewers watching 180 billion streams per year with nearly 2 trillion real-time transactions per day across more than 180 countries. Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth. The social media data consists of data from over 2000 accounts, over 5 million posts, 12.5 billion video views and over 35 billion engagements across Facebook, Instagram, Twitter and YouTube.
About Conviva
Conviva is the intelligence cloud for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, technology teams and customer care teams to build, engage and monetize their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 2 trillion streaming data events daily, supporting more than 500 million unique viewers watching 180 billion streams per year across 3.3 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005256/en/
Contact information
Paula Winkel, pr@conviva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
